SEC 13F Intelligence

Managers / Q4 2023 · view latest →

Lion Point Capital, LP

CIK 0001643354 · 375 PARK AVE, SUITE 2609, NEW YORK, NY, 10152 · 212-356-6200

Reported Value
$200M
Q4 2023
Positions
30
Filings on Record
31
2019–present window
Filed
Feb 14, 2024
original filing

Summary

Lion Point Capital, LP reported $200M in U.S.-listed holdings across 30 positions for Q4 2023.

The portfolio is heavily concentrated: SMTC alone accounts for 28.3% of reported value.

Compared with Q3 2023, the fund opened 2 new positions and exited 3.

Portfolio Metrics

Turnover
+9.0%
vs prior filed quarter
Top-10 Concentration
+51.6%
share of reported value
Largest Position
+28.3%
Semtech
New / Exited
2 / 3
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $636MQ4 ’18Q1 ’19: $1.1BQ2 ’19: $1.0BQ3 ’19: $897MQ4 ’19: $1.1BQ4 ’19Q1 ’20: $379MQ2 ’20: $412MQ3 ’20: $456MQ4 ’20: $519MQ4 ’20Q1 ’21: $550MQ2 ’21: $579MQ3 ’21: $533MQ4 ’21: $373MQ4 ’21Q1 ’22: $431MQ2 ’22: $878MQ3 ’22: $454MQ4 ’22: $703MQ4 ’22Q1 ’23: $243MQ2 ’23: $221MQ3 ’23: $224MQ4 ’23: $200MQ4 ’23Q1 ’24: $179MQ2 ’24: $55MQ3 ’24: $45MQ4 ’24: $19MQ4 ’24Q1 ’25: $16MQ2 ’25: $15MQ3 ’25: $18MQ4 ’25: $19MQ4 ’25Q1 ’26: $17Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 80.6%ETP: 16.6%Other: 2.5%US DOMESTIC: 0.3%
  • Common Stock · 80.6% · $161M
  • ETP · 16.6% · $33M
  • Other · 2.5% · $5M
  • US DOMESTIC · 0.3% · $670,740

Quarter-over-Quarter Changes full breakdown →

vs Q3 2023 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
ENPHYS ACQUISITION CORPNEW+78.1K78.1K+$833,594$833,594
AMLXAMYLYX PHARMACEUTICALS INCNEW+14.0K14.0K+$206,080$206,080
MISTMILESTONE PHARMACEUTICALS INADDED+1.20M1.65M+$1M$3M
HARPUSDHARPOON THERAPEUTICS INCADDED+146.4K228.9K+$2M$3M
SPDR S&P 500 ETF TRUSTSOLD OUT−50.0K0−$21M$0
DC8ADURECT CORPSOLD OUT−427.5K0−$1M$0
CHVCHEVRON CORP NEWSOLD OUT−460−$7,757$0
MCRB1EURSERES THERAPEUTICS INCTRIMMED−351.0K340.8K−$1M$477,065

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2023

26 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1SMTCSEMTECH CORPhistory →COM28.26%$56M2.58M
2MARINUS PHARMACEUTICALS INCCOM NEW11.61%$23M2.13M
3ARDXARDELYX INChistory →COM3.57%$7M1.15M
4MISTMILESTONE PHARMACEUTICALS INhistory →COM1.38%$3M1.65M
5HARPUSDHARPOON THERAPEUTICS INChistory →COM NEW1.30%$3M228.9K
60LSBURGERFI INTERNATIONAL INCCOM · *W EXP 12/16/2021.23%$2M4.83M
7KINIKSA PHARMACEUTICALS LTDCOM CL A1.15%$2M130.7K
8IM8NINSMED INChistory →COM PAR $.011.09%$2M70.3K
9BATLBATTALION OIL CORPORATIONhistory →COM1.07%$2M222.2K
10CYMABAY THERAPEUTICS INCCOM0.97%$2M82.4K
11TVTXTRAVERE THERAPEUTICS INCCOM · NOTE 2.250% 3/00.69%$1M1.08M
12FRXFENNEC PHARMACEUTICALS INCCOM0.62%$1M110.0K
13AVADEL PHARMACEUTICALS PLCSPONSORED ADR0.57%$1M80.0K
14ENPHYS ACQUISITION CORPCL A ORD SHS0.42%$833,59478.1K
15SNDXSYNDAX PHARMACEUTICALS INCCOM0.37%$745,54534.5K
16BLUEBIRD BIO INCCOM0.37%$733,133531.3K
17HUMAHUMACYTE INCCOM0.33%$667,400235.0K
18MCRB1EURSERES THERAPEUTICS INCCOM0.24%$477,065340.8K
19MIRMMIRUM PHARMACEUTICALS INCCOM0.20%$398,52013.5K
20REPLREPLIMUNE GROUP INCCOM0.18%$358,27542.5K
21LUMOS PHARMA INCCOM0.14%$288,72590.8K
22AMLXAMYLYX PHARMACEUTICALS INCCOM0.10%$206,08014.0K
23WHWKAADI BIOSCIENCE INCCOM0.08%$166,49482.4K
24ACRSACLARIS THERAPEUTICS INCCOM0.06%$121,693115.9K
25MSFTMICROSOFT CORPCOM0.02%$37,604100
26GOOGALPHABET INCCAP STK CL C0.01%$14,093100

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$17M35May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$19M39Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$18M27Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$15M19Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$16M21May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$19M19Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$45M25Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$55M27Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$179M32May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$200M30Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$224M31Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$221M30Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$243M31May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$703M32Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$454M41Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$878M40Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$431M35May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$373M33Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$533M38Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$579M34Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$550M30May 19, 2021RESTATEMENTchanges · EDGAR ↗
Q4 2020$519M24Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$456M24Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$412M24Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$379M25May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$1.1B26Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$897M26Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$1.0B24Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$1.1B24May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$636M35Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.